Motivation Alcohol consumption is one of the major risk factors of cardiovascular disease (CVD). Excessive alcohol drinking is the fifth leading cause of death worldwide and the prevalence of alcohol abuse continues to increase especially in low-income areas of sub-Saharan Africa. The alarming rate of urbanisation seems to be the driving force for excessive alcohol intake in the developing world. In addition to its influence on CVD, heavy drinking also results in a number of non-cardiovascular consequences that include injury, risky sexual behaviour, violent crime and family dysfunction among black South Africans, contributing to high mortality. Moreover, the highest number of individuals with human immunodeficiency virus (HIV) infection in South Africa is partly attributable to high intake of alcohol. HIV remains a major concern in South Africa with significant funding diverted to address the pandemic. The continued increases in mortality from preventable outcomes such as stroke, myocardial infarction and renal failure are largely due to urbanisation, poverty and dysfunctional health systems working with limited budgets. These are some of the factors requiring in-depth study of the scientific aspects of alcohol intake in South Africa. Although there is enough evidence that links excessive drinking with hypertension and CVD, the markers of alcohol intake – self reporting of alcohol, gamma-glutamyltransferase (GGT) and carbohydrate deficient transferrin – are still not specific enough to isolate other confounding factors in the association of alcohol intake with CVD. The markers of alcohol that independently predict CVD and mortality need to be explored. Finally, the severe lack of longitudinal investigations on alcohol-related hypertension development and total mortality in black South Africans has compromised the early identification of risk factors associated with these outcomes. This study will therefore attempt to address the limited availability of longitudinal studies and stimulate interest for continued investigation. Aim The aim of this study was to investigate whether alcohol intake of black South Africans is related to specific measures of cardiovascular function (change in blood pressure (BP), hypertension development) and mortality over a period of 5 years. Methodology This study was based on the international Prospective Urban and Rural Epidemiology (PURE) study which includes 26 countries, investigating the cause and development of cardiovascular risk factors in low, middle and high income countries. This South African leg of the PURE study started in 2005 in which the baseline data was collected from 2021 black South Africans from rural and urban areas in Ikageng, Ganyesa and Tlakgameng in the North West Province. Eleven participants presented with missing data, leaving 2010 participants with complete datasets at baseline. However, data from these 11 participants was useful, especially for Chapter 4. All participants gave informed consent and the Ethics committee of the North-West University (Potchefstroom Campus) approved the study. The follow-up data collection was done in 2010. General health questionnaires, anthropometric measurements, lipid profiles and cardiovascular measurements were taken both at baseline and follow-up using appropriate methods. We also collected blood samples and performed biochemical analyses for lipid markers, liver enzymes, inflammatory markers and percentage carbohydrate deficient transferrin (%CDT). Finally, we obtained data on cardiovascular and non-cardiovascular mortality through verbal autopsy and death certificates. We made use of analysis of variance (ANOVA) and Chi-square tests to compare means and proportions, respectively. We used dependent t-tests and the McNemar test to compare baseline and follow-up variables. Furthermore, we employed single and partial linear regression analyses to correlate alcohol markers with each other and with the cardiovascular measures. Multiple regression analyses were used to correlate dependent variables in the study with various independent variables as required. Finally, we employed multivariable-adjusted Cox regression analyses to assess the association of the selected alcohol markers with mortality while adjusting for several independent variables. Results and Conclusions of each manuscript - With the first research article (Chapter 4), we aimed to compare self-reported alcohol intake estimates with GGT and %CDT, considering their relationship with percentage change in brachial blood pressure (BP) and central systolic blood pressure (cSBP) over 5 years. The results indicated that only self-reported alcohol intake independently predicted % change in brachial BP and cSBP. This was not found for the biochemical markers GGT and %CDT. Self-reported alcohol intake seems to be an important measure to implement by health systems in low income areas of sub-Saharan Africa, where honest reporting is expected. - Given the likely presence of high GGT levels in both alcohol consumption and non-alcoholic fatty liver disease (NAFLD), the second manuscript (Chapter 5) aimed to compare the cardiovascular and metabolic characteristics of excessive alcohol users and individuals with suspected NAFLD (confirmed with self-report, GGT and %CDT). We found that different sex and cardiometabolic profiles characterised excessive alcohol users and individuals suspected with NAFLD. Lean body mass and male sex were the dominant characteristics in excessive alcohol use while the NAFLD group had a dysmetabolic profile with obese women making up the higher proportion of this group. In excessive alcohol users systolic blood pressure and pulse pressure were independently associated with high-density lipoprotein cholesterol. Diastolic blood pressure showed a significant correlation with waist circumference. These disparate profiles may guide healthcare practitioners in primary healthcare clinics to identify individuals with elevated GGT levels who may suffer from NAFLD or alcohol overuse. These results emphasise the importance of modifiable risk factors as the main contributors to CVD and that lifestyle change should be the main focus in developing countries such as South Africa. - The third manuscript (Chapter 6) aimed to determine the measure of alcohol intake (selfreported alcohol intake, GGT and %CDT) that related best with hypertension development, cardiovascular and all-cause mortality over 5 years in the same population of black South Africans. We found that GGT was the only independent predictor of hypertension development, cardiovascular as well as all-cause mortality. Moreover, self-reporting of alcohol intake predicted incident hypertension, confirming our findings from Chapter 4. The third marker, %CDT, a highly specific marker of alcohol intake, was not related with any outcome variable, perhaps due to its low sensitivity. Although self-reported alcohol intake is useful in low-resource primary healthcare settings, measurement of GGT is encouraged due to its predictive value for hypertension and mortality. GGT represents alcohol intake, non-alcoholic steatohepatitis and obesity - all known to have severe cardiovascular consequences. Discussion and Conclusions Excessive alcohol intake remains a major concern in the development of hypertension, CVD and premature death in sub-Saharan Africa. Despite their weaknesses such as bias and nonspecificity, self-reporting of alcohol consumption and GGT emerged as reliable alcohol markers that independently predicted 5-year change in BP, hypertension development and total mortality in this population. Serum %CDT did not show any association with the mentioned cardiovascular markers. Finally, we were also able to show that black South Africans with suspected NAFLD (i.e. with high GGT levels who do not consume alcohol) are typically obese women, whereas lean men were more likely to have high alcohol consumption. Further prospective investigations are encouraged regarding (a) these mentioned associations, as well as (b) other self-reporting estimates such as quantity and frequency of drinking and (c) the use of %CDT as a highly specific marker of alcohol intake. The simultaneous presence of HIV infection in alcohol abuse in this population also warrants further investigation. / PhD (Physiology), North-West University, Potchefstroom Campus, 2015

Motivation Alcohol consumption is one of the major risk factors of cardiovascular disease (CVD). Excessive alcohol drinking is the fifth leading cause of death worldwide and the prevalence of alcohol abuse continues to increase especially in low-income areas of sub-Saharan Africa. The alarming rate of urbanisation seems to be the driving force for excessive alcohol intake in the developing world. In addition to its influence on CVD, heavy drinking also results in a number of non-cardiovascular consequences that include injury, risky sexual behaviour, violent crime and family dysfunction among black South Africans, contributing to high mortality. Moreover, the highest number of individuals with human immunodeficiency virus (HIV) infection in South Africa is partly attributable to high intake of alcohol. HIV remains a major concern in South Africa with significant funding diverted to address the pandemic. The continued increases in mortality from preventable outcomes such as stroke, myocardial infarction and renal failure are largely due to urbanisation, poverty and dysfunctional health systems working with limited budgets. These are some of the factors requiring in-depth study of the scientific aspects of alcohol intake in South Africa. Although there is enough evidence that links excessive drinking with hypertension and CVD, the markers of alcohol intake – self reporting of alcohol, gamma-glutamyltransferase (GGT) and carbohydrate deficient transferrin – are still not specific enough to isolate other confounding factors in the association of alcohol intake with CVD. The markers of alcohol that independently predict CVD and mortality need to be explored. Finally, the severe lack of longitudinal investigations on alcohol-related hypertension development and total mortality in black South Africans has compromised the early identification of risk factors associated with these outcomes. This study will therefore attempt to address the limited availability of longitudinal studies and stimulate interest for continued investigation. Aim The aim of this study was to investigate whether alcohol intake of black South Africans is related to specific measures of cardiovascular function (change in blood pressure (BP), hypertension development) and mortality over a period of 5 years. Methodology This study was based on the international Prospective Urban and Rural Epidemiology (PURE) study which includes 26 countries, investigating the cause and development of cardiovascular risk factors in low, middle and high income countries. This South African leg of the PURE study started in 2005 in which the baseline data was collected from 2021 black South Africans from rural and urban areas in Ikageng, Ganyesa and Tlakgameng in the North West Province. Eleven participants presented with missing data, leaving 2010 participants with complete datasets at baseline. However, data from these 11 participants was useful, especially for Chapter 4. All participants gave informed consent and the Ethics committee of the North-West University (Potchefstroom Campus) approved the study. The follow-up data collection was done in 2010. General health questionnaires, anthropometric measurements, lipid profiles and cardiovascular measurements were taken both at baseline and follow-up using appropriate methods. We also collected blood samples and performed biochemical analyses for lipid markers, liver enzymes, inflammatory markers and percentage carbohydrate deficient transferrin (%CDT). Finally, we obtained data on cardiovascular and non-cardiovascular mortality through verbal autopsy and death certificates. We made use of analysis of variance (ANOVA) and Chi-square tests to compare means and proportions, respectively. We used dependent t-tests and the McNemar test to compare baseline and follow-up variables. Furthermore, we employed single and partial linear regression analyses to correlate alcohol markers with each other and with the cardiovascular measures. Multiple regression analyses were used to correlate dependent variables in the study with various independent variables as required. Finally, we employed multivariable-adjusted Cox regression analyses to assess the association of the selected alcohol markers with mortality while adjusting for several independent variables. Results and Conclusions of each manuscript - With the first research article (Chapter 4), we aimed to compare self-reported alcohol intake estimates with GGT and %CDT, considering their relationship with percentage change in brachial blood pressure (BP) and central systolic blood pressure (cSBP) over 5 years. The results indicated that only self-reported alcohol intake independently predicted % change in brachial BP and cSBP. This was not found for the biochemical markers GGT and %CDT. Self-reported alcohol intake seems to be an important measure to implement by health systems in low income areas of sub-Saharan Africa, where honest reporting is expected. - Given the likely presence of high GGT levels in both alcohol consumption and non-alcoholic fatty liver disease (NAFLD), the second manuscript (Chapter 5) aimed to compare the cardiovascular and metabolic characteristics of excessive alcohol users and individuals with suspected NAFLD (confirmed with self-report, GGT and %CDT). We found that different sex and cardiometabolic profiles characterised excessive alcohol users and individuals suspected with NAFLD. Lean body mass and male sex were the dominant characteristics in excessive alcohol use while the NAFLD group had a dysmetabolic profile with obese women making up the higher proportion of this group. In excessive alcohol users systolic blood pressure and pulse pressure were independently associated with high-density lipoprotein cholesterol. Diastolic blood pressure showed a significant correlation with waist circumference. These disparate profiles may guide healthcare practitioners in primary healthcare clinics to identify individuals with elevated GGT levels who may suffer from NAFLD or alcohol overuse. These results emphasise the importance of modifiable risk factors as the main contributors to CVD and that lifestyle change should be the main focus in developing countries such as South Africa. - The third manuscript (Chapter 6) aimed to determine the measure of alcohol intake (selfreported alcohol intake, GGT and %CDT) that related best with hypertension development, cardiovascular and all-cause mortality over 5 years in the same population of black South Africans. We found that GGT was the only independent predictor of hypertension development, cardiovascular as well as all-cause mortality. Moreover, self-reporting of alcohol intake predicted incident hypertension, confirming our findings from Chapter 4. The third marker, %CDT, a highly specific marker of alcohol intake, was not related with any outcome variable, perhaps due to its low sensitivity. Although self-reported alcohol intake is useful in low-resource primary healthcare settings, measurement of GGT is encouraged due to its predictive value for hypertension and mortality. GGT represents alcohol intake, non-alcoholic steatohepatitis and obesity - all known to have severe cardiovascular consequences. Discussion and Conclusions Excessive alcohol intake remains a major concern in the development of hypertension, CVD and premature death in sub-Saharan Africa. Despite their weaknesses such as bias and nonspecificity, self-reporting of alcohol consumption and GGT emerged as reliable alcohol markers that independently predicted 5-year change in BP, hypertension development and total mortality in this population. Serum %CDT did not show any association with the mentioned cardiovascular markers. Finally, we were also able to show that black South Africans with suspected NAFLD (i.e. with high GGT levels who do not consume alcohol) are typically obese women, whereas lean men were more likely to have high alcohol consumption. Further prospective investigations are encouraged regarding (a) these mentioned associations, as well as (b) other self-reporting estimates such as quantity and frequency of drinking and (c) the use of %CDT as a highly specific marker of alcohol intake. The simultaneous presence of HIV infection in alcohol abuse in this population also warrants further investigation. / PhD (Physiology), North-West University, Potchefstroom Campus, 2015

Abstract : Pro-inflammatory cytokines play a key role in pathogenesis of obesity and non-alcoholic fatty liver disease (NAFLD). IL-15 is a pro-inflammatory cytokine, which signals through a receptor complex composed of the IL-15 receptor (IL-15R) alpha chain, the IL-2/IL-15R beta chain and the common gamma chain. The functions of IL-15 have been extensively described in immune cells but less is known about its functions in others tissues such as the liver. The aim of this thesis is to investigate the role of IL-15 in fatty liver disease. C57BL/6 wildtype (WT) and IL-15 knockout (Il15[superscript -/-]) mice were maintained on high fat diet (HFD) or normal control diet (NCD). After 16 weeks, body weight, liver mass, fat accumulation in the liver, serum lipid levels and gene expression in the liver were evaluated. Intrahepatic lymphocytes (IHL) were also analysed. Primary hepatocytes were stimulated with IL-15 and chemokines gene expression was studied. IHLs were examined in WT, Il15[superscript -/-] and Il15ra[superscript -/-], as well as in macrophage- and hepatocyte-specific Il15ra[superscript -/-] mice. We found that IL-15 deficiency prevents weight gain and accumulation of lipids in the liver. Circulating levels of cholesterol and non-esterified fatty acids were elevated in WT mice but not in Il15[superscript -/-] mice. Hepatic expression of chemokines such as Ccl2, Ccl5 and Cxcl10 was increased in WT mice under HFD, but not in Il15[superscript -/-] mice. The livers of Il15[superscript -/-] and Il15ra[superscript -/-] mice also showed decreased expression of Tnfa and iNOS, and macrophage markers Cd68 and F4/80. Accordingly, stimulation of primary hepatocytes with IL-15 induced chemokine gene expression in WT but not in Il15ra[superscript -/-] hepatocytes. Furthermore, hepatocyte-specific ablation of IL-15Rαreduced infiltration of NK and NKT cells in the liver, suggesting that IL15Rα expression in the hepatocytes is needed for the recruitment and/or maintenance of the NK cell population in the liver. In conclusion, IL-15 promotes fat accumulation in the liver, and this is associated with increased inflammatory response in the liver. Increased availability of IL-15 in obesity may stimulate hepatocytes to secrete chemokines that promote hepatic inflammation resulting in fatty liver disease. IL-15Rα expression in hepatocytes appears to play a role in the maintenance of NK, NKT and iNKT cells. // Résumé : Les cytokines pro-inflammatoires jouent un rôle important dans la pathogenèse de l’obésité et la stéatose hépatique. L'IL-15 est une cytokine pro-inflammatoire qui est trans-présentée par l'IL-15Rα aux chaines IL-2/IL-15Rβ et γc. La fonction de l'IL-15 a été largement décrite dans les cellules immunitaires, mais ses fonctions dans d'autres tissus sont moins connues. Le but de ce mémoire est d'élucider le rôle de l'IL-15 dans la stéatose hépatique. Les souris C57BL/6 de type sauvage (WT) et Il15[indice supérieur -/-] ont été soumises à un régimehyperlipidique (HFD) ou à un régime normal. Après 16 semaines, le poids corporel, lamasse hépatique, l'accumulation de lipides dans le foie, les taux de lipides sériques et l'expression des différents gènes reliés à l’inflammation et au métabolisme dans le foie ont été évalués. Les lymphocytes intra-hépatiques (IHL) ont été également étudiés. Des hépatocytes primaires ont été stimulés avec IL-15, et l'expression génique de chimiokines a été déterminée. Les populations de IHLs ont été également caractérisées chez les souris WT, Il15[indice supérieur -/-] et Il15ra[indice supérieur -/-], ainsi que chez des souris dont la déficience dans l’expression d’IL-15Rα est ciblée aux macrophages ou aux hépatocytes. Nos résultats montrent que la déficience en IL-15 empêche l'accumulation de lipides dans le foie. Les taux de cholestérol et d’acides gras non estérifiés dans le sang étaient élevés chez les souris WT, mais pas chez les souris Il15[indice supérieur -/-]. L'expression hépatique des chimiokines Ccl2, Ccl5, Cxcl10 et des marqueurs de macrophages était augmentée chez les souris WT sous HFD, mais pas chez les souris Il15[indice supérieur -/-]. La stimulation des hépatocytes primaires avec l'IL-15 induit l'expression des gènes des chimiokines chez les hépatocytes WT, mais pas chez les Il15ra[indice supérieur -/-]. En outre, nous avons trouvé une infiltration réduite des cellules NK et NKT dans le foie des souris déficientes en Il15ra[indice supérieur -/-] dans les hépatocytes, ce qui suggère que l'expression d’IL15Rα chez les hépatocytes est nécessaire aurecrutement des cellules NK, NKT et / ou à leur maintien. En conclusion, nous proposons que l’IL-15 favorise l'accumulation de lipides dans le foie, et que ceci est associée à une réponse inflammatoire accrue. La disponibilité accrue de l'IL-15 dans l'obésité pourrait stimuler les hépatocytes à secréter des chimiokines ce qui favorise l'inflammation hépatique et conduirait à la stéatose hépatique. L’expression de l'IL-15Rα dans les hépatocytes semble jouer un rôle principal dans l’infiltration des cellules NK, NKT et iNKT dans le foie.

O carcinoma hepatocelular (HCC) é a sexta neoplasia mais comum e a terceira causa de mortalidade por câncer no mundo. Está relacionado, principalmente, à exposição a diversos fatores de risco, como a doença hepática gordurosa não alcoólica (NAFLD). O HCC apresenta mau prognóstico; neste sentido, é importante a adoção de medidas de controle, como a quimioprevenção. A quimioprevenção é o método mais apropriado para se evitar o câncer e consiste na prevenção, inibição ou reversão das etapas iniciais da carcinogênese, pela administração de um ou mais compostos químicos sintéticos ou naturais. Diversos compostos presentes nos alimentos podem apresentar atividade quimiopreventiva, dentre esses, a tributirina (TB), pró-fármaco do ácido butírico. Dessa forma, propôs-se avaliar o efeito quimiopreventivo da TB nas etapas de iniciação/promoção inicial, em ratos submetidos ao modelo de hepatocarcinogênese do hepatócito resistente (RH) associado à NAFLD. Ratos Wistar machos foram distribuídos em Grupo dos animais não tratados (NT), e dois outros grupos experimentais, o grupo RH + NAFLD + maltodextrina (grupo controle isocalórico, CI), e o grupo RH + NAFLD + tributirina (grupo TB). Os animais do grupo CI foram tratados diariamente, por gavagem, com emulsão hiperlipídica [1 mL/100 g de peso corpóreo (p. c)], e maltodextrina (300 mg/ 100 g p.c.), enquanto que os animais do Grupo TB foram tratados diariamente, por gavagem, com emulsão hiperlipídica [1 mL/100 g de p. c.], e TB (200 mg/ 100 g de p.c.), durante 13 semanas consecutivas quando foram eutanasiados. Após esse período, a análise por cromatografia a gás revelou que o grupo dos animais tratados com a tributirina apresentou uma concentração de AB 2.118 vezes superior (p < 0.05) às concentrações de AB constatadas no grupo controle. Em relação aos dados de morfometria de LPNs [lesões pré-neoplásicas persistentes (pLPN) ou em remodelação (rLPN)], a atividade quimiopreventiva da tributirina foi observada a partir da redução (p < 0,05) significativa do número de lesões pré-neoplásicas persistentes (pLPN) em comparação ao grupo controle. A área das pLPNs, contudo, foi maior (p < 0,05) no Grupo TB quando comparada à do grupo controle isocalórico. Não foram observadas diferenças estatisticamente significativas (p >= 0,05) no número e na área de rLPN, bem como na % da área do corte do fígado ocupada por LPNs entre os dois grupos experimentais. A quantificação da apoptose por H&E revelou maior (p < 0,05) índice apoptótico em pLPN e em rLPN nos animais tratados com TB, quando comparados aos animais do grupo 6 controle. Nesse sentido, observou-se que os animais tratados com a tributirina apresentaram maior (p < 0,05) ativação de Caspase 3 do que os ratos do grupo controle isocalórico. Em relação à avaliação da proliferação celular, o Grupo TB apresentou redução (p < 0,05) do índice de proliferação tanto em pLPNs como em rLPNs, quando comparado ao do grupo controle isocalórico. Não foi observada diferença estatisticamente significativa (p > 0,05) entre os surroundings dos dois grupos experimentais. A determinação do perfil lipídico sérico revelou que os animais tratados com a tributirina apresentaram menores (p < 0,05) concentrações séricas de LDL-colesterol e maiores (p < 0,05) concentrações séricas de HDL-colesterol, quando comparados às do grupo controle. Além disso, foram observadas menores (p < 0,05) concentrações hepáticas de colesterol no Grupo TB quando comparadas às do Grupo CI. Em relação a análise por PAS, embora, o presente estudo não tenha revelado diferença estatisticamente significativa (p >= 0,05) entre os dois grupos experimentais, o score entre os graus de marcação por PAS apresentou tendência (p = 0,07) a ser maior nos animais tratados com a tributirina quando comparados aos ratos do grupo controle. Em relação à expressão gênica de FGF-21, o Grupo TB apresentou maior (p < 0,05) expressão em comparação a seu grupo controle (Grupo CI). Além disso, esses dados são corroborados por meio da marcação imunoistoquímica de FGF-21, que revelou que os animais tratados com a tributirina apresentaram maior (p < 0,05) score desta marcação quando comparados aos ratos do grupo controle isocalórico. A análise de expressão em nível proteico de PPAR-&#945; revelou que o Grupo TB apresentou maior (p < 0,05) expressão em comparação ao Grupo CI. O presente estudo demonstrou que o tratamento com a tributirina apresentou um efeito quimiopreventivo quando administrada nas etapas de iniciação/promoção inicial em modelo de hepatocarcinogênese associado à NAFLD. Adicionalmente, sugere-se que a atividade como HDACi da TB poderia modular a expressão de genes supressores de tumor, bem como a daqueles relacionados ao metabolismo lipídico, atenuando os fatores de risco relacionados à NAFLD. / Hepatocellular carcinoma (HCC) is the sixth most common neoplasm and the third leading cause of cancer mortality in the world. It is mainly related to exposure to several risk factors, such as non-alcoholic fatty liver disease (NAFLD). HCC presents poor prognosis; In this sense, it is important to adopt control measures, such as chemoprevention. Chemoprevention is the most appropriate method to avoid cancer and consists in the prevention, inhibition or reversal of the early stages of carcinogenesis by the administration of one or more synthetic or natural chemical compounds. Several compounds present in foods may present chemopreventive activity, among them, tributyrin (TB), a prodrug of butyric acid. Thus, it was proposed to evaluate the chemopreventive effect of TB in the initiation / initial promotion stages in rats submitted to the hepatocyte-resistant hepatocyte model (HR) associated with NAFLD. Male Wistar rats were divided into two groups: RH + NAFLD + maltodextrin (isocaloric control group, CI), and RH + NAFLD + tributyrin group (TB group). The animals of the CI group were treated daily with gavage with hyperlipid emulsion [1 mL / 100 g body weight (wt.)], and maltodextrin (300 mg / 100 g body wt.), while the animals of the TB Group were treated daily by gavage with hyperlipid emulsion [1 mL / 100 g of body wt.], and TB (200 mg / 100 g body wt.) for 13 consecutive weeks when they were euthanized. After this period, the gas chromatographic analysis revealed that the group of animals treated with tributyrin had a concentration of AB 2184 times higher (p < 0.05) than the concentrations of AB found in the control group. Regarding the morphometry data of PNLs [persistent pre-neoplastic lesions (pPNL) or remodeling (rPNL)], the chemopreventive activity of tributyrin was observed from a significant (p < 0.05) reduction in the number of pPNL compared to the control group. The area of the pPNLs, however, was higher (p < 0.05) in the TB Group when compared to the isocaloric control group. There were no statistically significant differences (p >= 0.05) in the number and area of rPNL, as well as in the area of the cut of the liver occupied by LPNs between the two experimental groups. The quantification of apoptosis by H&E revealed a higher (p < 0.05) apoptotic index in pPNL and rPNL in the TB treated animals, when compared to the animals in the control group. In this sense, animals treated with tributyrin showed greater (p < 0.05) activation of Caspase 3 than the rats of the isocaloric control group. In relation to the evaluation of cell proliferation, the TB group presented a reduction (p < 0.05) in the proliferation index in both pPNLs and rPNLs, when compared to the isocaloric control group. No statistically significant difference (p> 0.05) was observed between the two experimental groups. The determination of serum lipid profile revealed that the animals treated with tributyrin showed lower (p < 0.05) serum LDL-cholesterol concentrations and higher (p < 0.05) serum HDL-cholesterol concentrations when compared to those in the group control. In addition, lower hepatic concentrations (p < 0.05) of cholesterol were observed in the TB Group when compared to those in the CI Group. Regarding the SBP analysis, although the present study did not reveal a statistically significant difference (p >= 0.05) between the two experimental groups, the score between the PAS presented a tendency (p = 0.07) to be greater in animals 8 treated with tributyrin compared to the rats in the control group. In relation to the gene expression of FGF-21, the TB Group presented higher (p <0.05) expression in comparison to its control group (CI Group). In addition, these data are corroborated by FGF-21 immunohistochemical labeling, which revealed that animals treated with tributyrin showed a higher (p <0.05) score for this marker when compared to the isocaloric control rats. Analysis of protein-level expression of PPAR-&#945; revealed that the TB Group had higher (p <0.05) expression compared to the CI Group. The present study demonstrated that treatment with tributyrin had a chemopreventive effect when administered in the initiation / initial promotion steps in a hepatocarcinogenesis model associated with NAFLD. In addition, it is suggested that the activity as HDACi of TB could modulate the expression of tumor suppressor genes, as well as those related to lipid metabolism, attenuating the risk factors related to NAFLD.

INTRODUÇÃO E OBJETIVOS: A doença hepática gordurosa não alcoólica (DHGNA) tem sido associada ao carcinoma hepatocelular (CHC), muitas vezes em paciente com hepatopatia avançada. Este estudo objetivou avaliar o efeito do sorafenibe no modelo experimental de CHC avançado secundário à DHGNA, padronizar o PET com 18F-FDG para avaliar o CHC neste modelo e avaliar se há relação entre o grau de avidez pelo 18F-FDG e o grau de diferenciação tumoral do CHC. METODOLOGIA: Estudo foi aprovado pela Comissão de Ética no Uso de Animais. Foram utilizados trinta ratos Sprague-Dawley, machos, com 3 meses de vida, pesando entre 300-400g. O CHC secundário à DHGNA foi induzido pela combinação de dieta hiperlipídica deficiente em colina e dietilnitrosamina na dose de 100 mg/ L na água de beber ad libitum por 16 semanas. Após este período foram suspensos os estímulos carcinogênicos, realizou-se ultrassonografia abdominal para caracterização dos nódulos hepáticos maiores que 2 mm, e foi feita a divisão dos dois grupos segundo randomização e iniciada a administração diária do fármaco por gavagem durante 3 semanas: Controle (n=10) - 1 mL salina, Sorafenibe (n=20): 5mg/ kg/ dia. Ao término do tratamento, os animais realizaram PET (Gamma Medica-Ideas, USA) com 18F-FDG (média de 18F-FDG injetada de 1,02 ± 0,17 mCi ou 37,7 ± 6,29 MBq). Três dias após o PET, os animais foram anestesiados e foi feita a eutanásia, quando foi coletado material hepático. As lâminas foram avaliadas, por patologista veterinário experiente, na coloração de hematoxilina-eosina e imunohistoquímica para glutamina sintetase, antígeno específico de hepatócitos 1 e citoqueratina-19. RESULTADOS: A mortalidade nos dois grupos foi de 60% (p=0,07). Os achados ultrassonográficos mostraram grupos homogêneos com média de nódulos por animal: 4,88 ± 2,75 no controle e 4,95 ± 3,11 no sorafenibe (p=0,48). Na 19ª semana, viu-se que a média de lesões hipercaptantes por animal no PET foi de 4,37 ± 1,59 no grupo sorafenibe e 8,5 ± 3,7 no controle (p=0,006). A avidez máxima do 18F-FDG (SUVmáx) foi diferente entre os grupos estudados: 2,4 ± 1,98 no sorafenibe e 3,8 ± 1,74 no controle (p=0,01). Houve correlação direta entre o CHC pouco diferenciado/indiferenciado e os maiores valores de SUVmed (R2 = 0,34, p=0,04), SUVmax (R2 = 0,44, p=0,01), relação Tumor SUVmax/Fígado SUVmax (R2 = 0,42, p=0,02) e relação Tumor SUVmax/ Músculo SUVmax (R2 = 0,54, p=0,006). A média por animal de CHC confirmado pela histologia foi menor no grupo sorafenibe que no controle (5,5 ± 1,5 vs 3,3 ± 0,48, p=0,01). E o grupo tratado com sorafenibe apresentou mais CHC bem diferenciado que o controle (39% vs 5%, respectivamente, p=0,01), bem como, menor presença de CHC pouco diferenciado que o grupo controle (52% vs 81%, p-0,003). CONCLUSÃO: O sorafenibe reduziu o número médio de CHC, a agressividade dos CHC e menor SUVmax dos tumores. A metodologia do PET foi padronizada para este modelo animal específico. O PET 18F-FDG pode ser utilizado para avaliar não invasivamente o grau de diferenciação histológica do CHC, pois valores maiores de SUVmed, SUVmax, Tumor SUVmax/Fígado SUVmax e Tumor SUVmax/ Músculo SUVmax foram correlacionados com CHC pouco diferenciado / BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) has been linked to hepatocellular carcinoma (HCC), often in patients with advanced liver disease. This study aimed to: assess the effect of sorafenib in the experimental model of NAFLD related HCC, standardize PET 18F-FDG to be an assessment tool of HCC in this model and to assess if there is a correlation between the degree of avidity for 18F-FDG and the degree of tumor differentiation. METHODS: The ethics committee on animal use approved this study. Thirty male sprague-dawley rats were used, weighing between 300-400g. NAFLD related HCC was induced by the combination of fat and choline deficient diet with diethylnitrosamine (100 mg/L) in drinking water for 16 weeks. After this period these carcinogenic stimuli were suspended, and liver nodules were identified by abdominal ultrasound. Two groups were randomized: control (n=10) and treatment (n=20). Rats received daily gavage administration of 1 mL saline in the control group and sorafenib (5mg/kg/day) in the treatment group. After treatment, animals performed PET (Gamma Medica-Ideas, USA) with 18F-FDG (average of 18F-FDG injected 1.02 ± 0.17 mCi or 37.7 ± 6.29 MBq). Three days after the PET, the animals were anesthetized and euthanized. Histological aspect was evaluated by experienced veterinary pathologist. RESULTS: The mortality in both groups was 60% (p = 0.07). The sonographic findings showed homogeneous groups with average nodules per animal of: 4.88 ± 2.75 in control and 4.95 ± 3.11 in sorafenib (p = 0.48). On the 19th week, it was observed that the average hypercaptant lesion per animal in PET was 4.37 ± 1.59 in the sorafenib group and 8.5 ± 3.7 in control group (p = 0.006). Average SUVmax was different between groups: 2.4 ± 1.98 in the sorafenib group and 3.8 ± 1.74 in the control group (p = 0.01). A direct correlation was found between the poorly differentiated HCC and larger values of: SUVmed (R2 = 0.34, p = 0.04), SUVmax (R2 = 0.44, p = 0.01) tumorSUVmax / LiverSUVmax ratio (R2 = 0.42, p = 0.02) and tumorSUVmax / MuscleSUVmax ratio (R2 = 0.54, p = 0.006). HCC average per animal was lower in the sorafenib group than in the control group (5.5 ± 1.5 vs. 3.3 ± 0.48; p = 0.01). And sorafenib group had more well differentiated HCC (39% vs 5%, respectively, p = 0.01) and lower presence of poorly differentiated HCC (52% vs 81%, p -0.003) than the control group. CONCLUSION: Sorafenib reduced the average number of HCC, the aggressiveness of HCC and lowered values of tumors SUVmax. The methodology of PET was standardized for this particular animal model. PET 18F-FDG can be used noninvasively to assess the degree of histological differentiation of HCC, as higher values of SUVmed, SUVmax, tumorSUVmax/ LiverSUVmax ratio and tumorSUVmax / MuscleSUVmax ratio were correlated with poorly differentiated HCC

Made available in DSpace on 2017-07-10T14:17:07Z (GMT). No. of bitstreams: 1 Claudia Ebertz.pdf: 1969807 bytes, checksum: 61f18bbc24e26e53d1b8941d93aadc58 (MD5) Previous issue date: 2013-12-17 / Purpose: Bariatric surgeries reduce non-alcoholic fatty liver disease (NAFLD), which is associated with metabolic syndrome co-morbidities; however, the effects of duodenal-jejunal bypass (DJB) have not been investigated. This study aimed to evaluate the effects of DJB on serum and hepatic profiles of obese rats fed on a western diet (WD). Methods: Male Wistar rats were fed a standard rodent chow diet (CTL group) or WD ad libitum. After 10 weeks, WD rats were submitted to sham (WD SHAM) or duodenal-jejunal bypass (WD DJB). Body weight, fat pad depots, glycemia, insulinemia, HOMA-IR, TyG, lipids profile and hepatic analyses were evaluated two months after surgery. Results: The WD SHAM group presented greater obesity, hyperglycemia, hyperinsulinemia, insulin resistance, hypertriglyceridemia and hepatic steatosis than the CTL group. WD DJB rats presented decreased serum glucose and insulin resistance, when compared to WD SHAM animals, without changes in insulinemia. In addition, DJB surgery normalized serum TG and attenuated TG accumulation and steatosis in the liver of the WD DJB group. Hepatic ACC and FAS protein expressions were similar in all groups. Conclusions: DJB attenuates hepatic parameters of NAFLD in obese rats fed on a WD diet / Introdução: Cirurgias bariátricas reducem a doença hepática gordurosa não alcoólica (DHGNA), a qual está associada a comorbidades da síndrome metabólica, entretanto, os efeitos da derivação duodeno-jejunal (DDJ) não foram investigados. Este estudo tem por objetivo avaliar os efeitos da DDJ no perfil sérico e hepático de ratos obesos submetidos à dieta de cafeteria. Métodos: Ratos Wistar foram alimentados com ração padrão para roedores (grupo CTL) ou dieta de cafeteria (grupo CAF) ad libitum. Após 10 semanas de dieta, os animais do grupo CAF foram submetidos à falsa cirurgia (CAF FO) ou à derivação duodeno-jejunal (CAF DDJ). O peso corporal, peso dos depósitos de gorduras, glicemia, insulinemia, HOMA-IR, índice TyG, perfil lipídico e análises hepáticas foram avaliados dois meses após a cirurgia. Resultados: O grupo CAF FC apresentou obesidade, hiperglicemia, hiperinsulinemia, resistência à insulina, hipertrigliceridemia e esteatose hepática em relação ao grupo CTL. Os animais CAF DDJ apresentaram diminuição da glicose sérica e resistência à insulina, sem alterações na insulinemia, quando comparados aos animais CAF FC. Além disso, a DDJ normalizou a concentração sérica de triglicérides e atenuou o acúmulo hepático de triglicérides, bem como a esteatose hepática no grupo CAF DDJ. A expressão proteica de ACC e FAS hepáticas foram similares nos três grupos. Conclusões: A DDJ atenuou os parâmetros hepáticos da DHGNA em ratos obesos por dieta de cafeteria

Introdução: A doença hepática gordurosa não alcoólica (DHGNA) é uma das formas mais comuns de doença hepática, que acomete cerca de 20% a 30% da população adulta, sendo encontrada mais frequentemente em indivíduos obesos (~90%). Dentre os principais fatores etiológicos estão: resistência à insulina, disfunção mitocondrial e estresse oxidativo. Até o presente momento não há tratamento farmacológico específico para a DHGNA, por isso modificações no estilo de vida como redução do peso corporal (PC), dieta e prática regular de exercício físico são eficazes no combate a DHGNA. Entretanto ainda não está elucidado quais os principais impactos do exercício físico na DHGNA. Objetivos: Com isso, propusemos um estudo experimental que avaliou o efeito do treinamento físico sobre metabolismo oxidativo, funcionalidade mitocondrial hepática e muscular (soléo) e lipogênese hepática em modelo de DHGNA em camundongos obesos (ob/ob). Métodos: Utilizou-se 14 (ob/ob) com déficit em leptina e forma divididos em dois grupos: Sedentário (SED)=7 e treinados (TF=7) de acordo com o equilíbrio na média do PC. Estes animais foram submetidos a um protocolo de 8 semanas de treinamento físico aeróbio (TFA) a 60% da velocidade máxima obtida no teste de corrida realizado no último dia da semana de adaptação ao TFA. Na quarta semana foi realizado o reajuste da intensidade apenas nos TF e o teste de capacidade de corrida foi aplicado na oitava semana em ambos os grupos para se avaliar o desempenho dos animais nas variáveis ligadas ao TFA. Avaliou-se durante todo o protocolo: peso corporal (PC) em média, percentual, evolução do PC e consumo de água e ração. Na expressão gênica intra-hepática e muscular foram analisados: PGC-1Alfa, CPT-1Alfa e PPAR-Alfa relacionados a funcionalidade mitocondrial, em adição analisou-se no fígado: SREBP1. No metabolismo oxidativo analisou-se: biomarcadores (MDA e carbonilas), atividade enzimática de SOD, CAT e GST, sistema antioxidante não enzimático: sulfidrilas, GSH e GSH/GSSG, enzimas metabólicas (Citrato sintase e Beta-HAD). Foi realizada análise histopatológica hepática por HE, além do peso absoluto e relativo dos tecidos hepático e adiposo branco retroperitoneal, periepididimal e inguinal. Resultados: Na análise intergrupo em relação ao PC, observou-se redução significativa no grupo TF, assim como nos consumos de água e ração que foram significativamente menores após 8 semanas: Na análise de expressão gênica hepática encontramos aumento de PGC-1Alfa (p=0,002) e menor de CPT-1Alfa p=0,03) no grupo LTF após 8 semanas de TFA. No músculo Soléo encontramos maior expressão dos genes: PGC-1Alfa (p=0,002) e CPT-1Alfa (p=0,01). Em relação a MDA e carbonilas não houve diferença intergrupo, assim como em SOD, CAT e GST. Entretanto, quando analisamos o sistema antioxidante não enzimático, encontramos que os TF obtiveram maior nível de: sulfídrilas (p=0,02), GSH (p=0,001) e GSH/GSSG (p=0,02), além maior ativação das enzimas metabólicas: citrato sintase (p=0,004) e Beta-HAD (p=0,01). No peso dos órgãos, o TF demonstrou menor peso absoluto e relativo hepático e retroperitoneal. Na análise histológica, não houve diferença significante. Conclusões: Nossos dados demonstram que TFA melhorou o controle do PC, hiperfagia e peso do fígado e retroperitoneal, funcionalidade mitocondrial e metabolismo oxidativo em (ob/ob) com DHGNA. Há necessidade uma intervenção a longo prazo com TFA, para que se posso visualizar possíveis melhorias histológicas / Non-alcoholic fatty liver disease (NAFLD) is one of the most common forms of liver disease, affecting about 20% to 30% of the adult population, being found more often in obese individuals (~ 90%). Among the main etiological factors are insulin resistance, mitochondrial dysfunction and oxidative stress. To date, no specific pharmacological treatment for NAFLD, so lifestyle modifications such as: reduction in BW, diet and regular practice of physical exercise are effective, however it is not yet elucidated what the main impacts of physical exercise on NAFLD. Therefore, we proposed an experimental study that evaluated the effect of physical training on oxidative metabolism, hepatic and muscular mitochondrial function (soles) and hepatic lipogenesis in an ob / ob model of NAFLD. We used 14 (ob / ob) with leptin deficiency and divided into two groups: Sedentary (SED) = 7 and Trained (TF = 7) according to the mean BW balance. These animals were submitted to an 8-week protocol of aerobic physical training (AET) at 60% of the maximum velocity obtained in the running test performed on the last day of the week of adaptation to AET. In the fourth week the intensity adjustment was only done in the TF and the running capacity test was amplified in the eighth week in both groups to evaluate the performance of the animals in the variables linked to the AET. It was evaluated throughout the protocol: body weight (BW) on average, percentage, BW evolution and water and feed consumption. In the intrahepatic and muscular gene expression were analyzed: PGC-1Alpha, CPT-1Alpha and PPAR-Alpha related to mitochondrial functionality, in addition liver was analyzed: SREBP1. In the oxidative metabolism, we analyzed: biomarkers (MDA and carbonyls), enzymatic activity of SOD, CAT and GST, non-enzymatic anti-oxidant system: sulfhydryl, GSH and GSH / GSSG, metabolic enzymes (Citrate synthase and Beta-HAD). Hepatic histopathological analysis was performed by HE, in addition to the absolute and relative weight of the hepatic and white retroperitoneal, periepididimal and inguinal adipose tissues. In the intergroup analysis in relation to BW, a significant reduction was observed in the TF group, as well as in the water and feed intakes that were significantly lower after 8 weeks: In the analysis of hepatic gene expression we found an increase of PGC-1Alpha (p = 0.002) and CPT-1 = 0.0Alpha 3) in the TF group after 8 weeks of AET. In the soleus we found higher expression of the genes: PGC-1Alpha (p= 0.002) and CPT-1Alpha (p = 0.01). In relation to MDA and carbonyls there was no intergroup difference, as in SOD, CAT and GST. When we analyzed the non-enzymatic anti-oxidant system, we found that the TF had a higher activity of: sulfhydryls (p = 0.02), GSH (p = 0.001) and GSH / GSSG (p = 0.02) metabolic enzymes: citrate synthase (p = 0.004) and Beta-HAD (p = 0.01). In the weight of the organs the TF showed lower absolute and relative hepatic and retroperitoneal weight. In the histological analysis, there was no significant difference. Our data demonstrate that AET improved BW control, hyperphagia and liver and retroperitoneal weight, mitochondrial functionality and oxidative metabolism in (ob / ob) with NAFLD. Long-term AET intervention is needed so that we can visualize possible histological improvements. We considered the effective AET to improve aspects related to NAFLD

H2S é um gasotransmissor com atua regulando processos fisiológicos e fisiopatológicos. É sintetizado principalmente pelas enzimas cistationinagama-liase (CSE) e cistationina beta-sintase (CBS), ambas dependentes do co-fator 5-fosfato de pirodoxal, e que utilizam o L-cisteína como substrato. Essas enzimas estão presentes no fígado. O camundongo knockout para CBS (CBS KO) apresenta fenótipo de homocistinúria, ou seja, além da homocisteinemia apresenta estresse oxidativo, fibrose e esteatose hepática. Ademais, há estudos in vitro sugerindo um papel desse gás reduzindo a captação de glicose hepática. A hipótese desse projeto é que haja redução precoce da produção de H2S pelo fígado de camundongos alimentados com dieta hiperlipídica (DHL) e esse seja um evento anterior à instalação do fígado gorduroso ou DGHNA associada à obesidade induzida pela DHL, DIO. Para isso, avaliamos a evolução ponderal, consumo alimentar e calórico diários, a tolerância a glicose e a insulina (GTT, ITT e Kitt), a morfohistologia hepática com corantes HE e picrocirius red, expressão proteica e gênica das enzimas CBS e CSE, a quantificação do conteúdo de triglicérides, a deteção de F4/80 e a atividade de enzimas antioxidantes (catalase, GPx e arginase) em amostras de fígado de camundongos machos C57Bl6 alimentados com a DHL por 5 períodos distintos (10, 20, 40, 60 e 80 dias de dieta). Detectamos aumento da massa corporal final a partir de 20 dias de DHL. O consumo alimentar diário foi menor nos animais com a DHL, porém com maior consumo calório do que os respectivos controles. A glicemia basal foi maior nos animais com DHL desde os 10 dias, com exceção o grupo com 40 dias. Houve maior intolerância à glicose desde 10 dias de DHL seguida de resistência à insulina a partir de 20 dias de DHL. Foi detectada presença de vacúolos intracelular nos hepatócitos a partir de 20 dias de DHL, no entanto, a presença de hepatócitos comprometidos foi de aproximadamente 2% aos 20 dias da DHL, cerca de 5% aos 40 dias da DHL e aproximadamente 60% com 60 e 80 dias da DHL. Aos 80 dias de DHL foi detectada balonização de hepatócitos, presença de infiltrado inflamatório identificado pelo aumento da marcação com F4/80, maior detecção de fibras colágenas nos espaços vasculares e aumento da atividade da enzima sérica AST. Houve redução para aproximadamente 50% da produção do H2S nas amostras de fígado dos animais a partir de 40 dias da DHL, porém sem relação clara com as modificações detectadas na expressão das enzimas CBS e CSE. Diante desses dados, concluímos que a DHL leva à intolerância à glicose, seguida de aumento da massa corporal e resistência ao efeito hipoglicemiante da insulina e que o desenvolvimento de fígado gorduroso é um evento mais tardio. Vimos que o espectro da DGHNA desenvolvida apresenta características de esteato-hepatite incipiente, com balonização dos hepatócitos, infiltrado inflamatório presente, discreto aumento de deposição de fibras colágenas e aumento da enzima hepática circulante AST. A redução da produção do gás apareceu após a instalação da resistência à insulina, mas anterior ao estabelecimento da DGHNA. Portanto, concluímos que a alteração na produção hepática do H2S pode ser um evento precoce associado ao desenvolvimento da DGHNA e que merece ser investigado seu potencial papel na progressão de estatose a EHNA com fibrose e cirrose. No entanto, será importante buscar um outro modelo animal para estudo dessa evolução. / Hydrogen sulfide (H2S) is a gaseous signaling molecule that regulates a variety of physiological and pathophysiological processes. It is primarily synthesized by cystathionine-gamma-lyase (CSE) and cystathionine beta-synthase (CBS), which are expressed in the liver, require 5\'-pyrodoxal phosphate as a co-factor, and use L-cysteine as a substrate. Interestingly, CBS knockout (CBS KO) mice present homocystinuria and associated homocysteinemia, as well as oxidative stress, fibrosis and hepatic steatosis. Furthermore, in vitro studies suggest that this gas reduces hepatic glucose uptake. It was hypothesized that mice fed a high fat diet (HFD) would display an early reduction H2S production by the liver and that this event would occur prior to the establishment of fatty liver or NAFLD, which is associated with diet induced obesity (DIO). Towards the goal of gaining a better understanding of H2S production during the onset and progression of DIO, male C57B16 mice were fed a HFD for 10, 20, 40, 60 or 80 days. During the experimental period, weight evolution, daily food and caloric intake, as well as glucose and insulin tolerance (GTT, ITT and Kitt) were evalauted. At the end of each time period hepatocyte morphology was assessed by HE and picrocirius red staining, CBS and CSE gene and protein expression were evaluated, triglyceride content was quantified, F4/80 antigen was detected and antioxidant enzyme (catalase, GPx and arginase) activites were determined. The results showed that mice fed a HFD for 20 days or longer presented an increase in final body weight. All of the HFD groups presented reduced daily food intake, but higher caloric intake, when compared to their respective controls. All of the animals fed a HFD had increased basal glycemia levels, with the exception of the group fed the diet for 40 days. Reduced glucose tolerance and insulin resistance were observed after consuming the HFD for 10 and 20 days, respectively. Intracellular vacuoles were detected in the hepatocytes after 20 days of the HFD. The amount of compromised hepatocytes increased from 2% after 20 days of the HFD, to about 5% after 40 days, to approximately 60% after 60 and 80 days. After consuming the HFD for 80 days, there was an observed ballooning of hepatocytes, increased F4/80 detection indicating the presence of inflammatory infiltrates, increased collagen fiber detection in the vascular spaces, and increased serum AST activity. There was a ~50% reduction in H2S production in the liver samples from animals fed a HFD for 40 days; however, there was no clear relationship with the alterations detected in CBS and CSE gene or protein expression. Based on the results, it was concluded that an HFD promotes glucose intolerance, followed by increased body mass and insulin resistance and that the development of fatty liver occurs later. Additionally, the spectrum of the developed NAFLD presented incipient steatohepatitis characteristics, such as: hepatocyte ballooning, inflammatory infiltrate, a slight increase in collagen fiber deposition, and an increase in circulating liver AST levels. The reduction in H2S gas production appeared after the installation of insulin resistance, but prior to the establishment of NAFLD. Therefore, we conclude that alterations in hepatic H2S production may be an early event associated with the onset of NAFLD and that its potential role in the progression of steatosis and NASH with fibrosis and cirrhosis deserves to be investigated. However, it will be important to evaluate this evolution in other animal models.

Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro / A intervenção farmacológica pode minimizar ou até mesmo reverter o remodelamento adverso em órgãos num modelo de síndrome metabólica. Este trabalho teve como objetivo avaliar os efeitos das monoterapias e associações medicamentosas sobre a morfologia do tecido adiposo, remodelamento hepático e pancreático em camundongos C57bl/6 alimentados com dieta very high-fat. Camundongos C57bl/6 machos foram alimentados com dieta very high-fat (HF, 60% de lipídios) ou dieta padrão (SC, 10% de lipídios) por 10 semanas, quando foram iniciados os tratamentos: HF-T (HF + Telmisartana, 5.2mg/Kg/dia), HF-S (HF + Sitagliptina, 1.08g/Kg/dia), HF-M (HF + Metformina, 310.0mg/Kg/dia) e as associações medicamentosas HF-TM, HF-TS e HF-SM. Os grupos tratados também tiveram livre acesso à dieta high fat e os tratamentos duraram 6 semanas. Técnicas morfométricas, estereológicas, imunohistoquímicas, ELISA, western blotting e microscopia eletrônica foram utilizadas. A dieta high-fat causou sobrepeso, intolerância oral à glucose, hiperinsulinemia, hipertrofia de ilhotas e adipócitos, grau 2 de esteatose hepatica (<33%) redução da expressão de PPAR-alfa e de GLUT-2, concomitante com aumento da expressão de SREBP-1 no grupo HF (P<0.0001). Por outro lado, todos os tratamentos resultaram em perda de peso significativa, reversão da resistência à insulina, hipertrofia de ilhotas e adipócitos e alívio da esteatose hepática. Somente os grupos HF-T e HF-TS apresentaram massa corporal similar ao grupo SC ao final do experimento, sendo que o ultimo também apresentou reversão da esteatose hepática. O aumento da expressão do PPAR-alfa paralelamente ao decréscimo da expressão do SREBP-1 explica os achados favoráveis para o fígado. A normalização do tamanho do adipócito foi consistente com os níveis maiores de adiponectina e com a redução dos níveis de TNF-alfa (P<0.0001) nos grupos tratados.Todos os tratamentos foram eficazes para controlar a síndrome metabólica. Os melhores resultados foram alcançados com a telmisartana e sitagliptina como monoterapias ou como associação entre essas, combinando a ativação parcial do PPAR-alfa no fígado com a extensão do tempo de ação das incretinas / Pharmacological intervention can minimize or even reverse adverse remodeling due to metabolic syndrome. This work sought to evaluate the effects of monotherapies and combinations of drugs on insulin sensitivity, adipose tissue morphology, pancreatic and hepatic remodelling in C57BL/6 mice fed a high-fat diet. Male C57BL/6 mice were fed a very high-fat diet (HF, 60% lipids) or standard chow (SC, 10% lipids) over 10 weeks, after which drug treatments began: HF-T (HF + Telmisartan, 5.2mg/Kg/day), HF-S (HF + Sitagliptin, 1.08g/Kg/day), HF-M (HF + Metformin, 310.0mg/Kg/day) and the drug combinations HF-TM, HF-TS and HF-SM. Treated groups also had free access to HF diet and treatments lasted 6 weeks. Morphometry, stereological tools, immunostaining, ELISA, Western blotting and electron microscopy were used. The HF diet yielded an overweight phenotype, oral glucose intolerance, hyperinsulinemia, hypertrophied islets and adipocytes, stage 2 steatosis (<33%) and reduced liver PPAR-alpha and GLUT-2, concomitant with enhanced SREBP-1 expression, in the HF group (P<0.0001). Conversely, all drug treatments resulted in significant weight loss, reversed insulin resistance, islet and adipocyte hypertrophy and alleviated hepatic steatosis. Only HF-T and HF-TS presented body weights similar to SC mice at the end of the experiment and the latter treatment reversed hepatic steatosis. Increased PPAR-alpha immunostaining parallel to higher GLUT-2 and reduced SREBP-1 expression explain the favourable hepatic outcomes. Restoration of adipocyte size was consistent with higher adiponectin levels and lower TNF-alpha levels (P<0.0001) in treated groups. In conclusion, all treatments were effective in controlling metabolic syndrome. The best results were achieved using Telmisartan and Sitagliptin as monotherapies or as a dual treatment, combining partial PPAR-gamma agonism and PPAR-alpha activation in the liver with extended incretin action

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / As associações entre obesidade, doença hepática gordurosa não alcoólica (NAFLD) e diabetes mellitus tipo 2 (DM2) são bem estabelecidas, e o sistema renina-angiotensina (SRA) pode proporcionar uma ligação entre eles. O bloqueio do SRA em diferentes níveis pode estar relacionado a respostas na resistência à insulina, remodelagem do pâncreas e do fígado em um modelo de obesidade induzida por dieta. Camundongos C57BL/6 foram alimentados com uma dieta hiperlipídica (HF) durante oito semanas e depois tratados com alisquireno (50 mg/kg/dia), enalapril (30 mg/kg/dia) ou losartana (10 mg/kg/dia) por um período adicional de seis semanas. As drogas foram incorporadas na dieta. Avaliou-se a massa corporal (MC), pressão arterial, consumo e gasto energético (GE), metabolismo da glicose e lipídico, histopatologia pancreática e hepática, análise hormonal, imunohistoquímica, perfil gênico e/ou proteico do SRA no pâncreas, gliconeogênese hepática, sinalização da insulina, oxidação e acúmulo lipídico. Todos os inibidores do SRA reduziram significativamente o aumento da pressão arterial nos camundongos alimentados com dieta HF. O tratamento com enalapril, mas não alisquireno ou losartana, reduziu o ganho de MC e a ingestão alimentar; aumentou o GE; amenizou a intolerância à glicose e resistência à insulina; melhorou a massa de células alfa e beta; impediu a redução da adiponectina plasmática e restaurou a sensibilidade à leptina. Além disso, o tratamento com enalapril melhorou a expressão proteica nas ilhotas pancreáticas de Pdx1, GLUT2, ECA2 e do receptor Mas. O tratamento com losartana apresentou uma elevação na expressão proteica de AT2R no pâncreas. No fígado, a administração de enalapril atenuou a esteatose hepática, o acúmulo de triglicerídeos e preveniu o aumento dos níveis de PEPCK, G6Pase e do GLUT2. Do mesmo modo, o enalapril melhorou a transdução dos sinais da insulina através da via IRS-1/Akt, bem como reduziu os níveis de expressão gênica e/ou proteica de PPAR-gama, SREBP-1c e FAS. Esses resultados sugerem que a inibição da ECA com enalapril atenuou muitos efeitos deletérios provocados pelo consumo da dieta HF, incluindo: normalização da morfologia e função das ilhotas pancreáticas, proteção contra a resistência à insulina e acúmulo de lipídios no fígado. Estes efeitos protetores do enalapril podem ser atribuídos, principalmente, à redução no ganho de MC e ingestão alimentar, aumento do GE, ativação do eixo ECA2/Ang(1-7)/receptor Mas e dos níveis de adiponectina, o que promove uma melhora na ação hepática da insulina e leptina, normalização da gliconeogênese, amenizando a NAFLD. / The associations between obesity, NAFLD (non-alcoholic fatty liver disease) and diabetes are well established, and the reninangiotensin system (RAS) may provide a link among them. . The blocking of the RAS at different levels may be related to responses on insulin resistance, remodeling of the pancreas and liver in a model of diet-induced obesity. Mice (C57BL/6) were fed on a high-fat (HF) diet for 8 weeks and then treated with aliskiren (50 mg/kg/day), enalapril (30 mg/kg/day) or losartan (10 mg/kg/day) for an additional 6 weeks. The drugs were incorporated into the diet. We assessed body mass (BM), blood pressure, energy intake and expenditure (EE), glucose and lipid metabolism, pancreatic and hepatic histopathology, hormonal analysis, immunohistochemistry, the expression profile of genes and/or proteins affecting pancreas RAS, hepatic gluconeogenesis, insulin signaling and lipid oxidation and accumulation. All RAS inhibitors significantly attenuated the increased blood pressure in mice fed a HF diet. Treatment with enalapril, but not aliskiren or losartan, significantly attenuated BM gain, increased EE, enhanced the glucose intolerance and insulin resistance; improved the alpha and beta cell mass; prevented the reduction of plasma adiponectin and restored leptin sensibility. Furthermore, enalapril treatment improved the protein expression of the pancreatic islet Pdx1, GLUT2, ACE2 and Mas receptors. Losartan treatment showed the greatest AT2R expression in the pancreas. In the liver, the enalapril administration improved hepatic steatosis, triglycerides and prevented the increase hepatic protein levels of PEPCK, G6Pase and GLUT2. Additionally, enalapril improved the deleterious effects on the HF diet by upregulating the signal transduction through the IRS-1/Akt pathway, as well as downregulatin the protein levels and mRNA expression of PPAR-gamma, SREBP-1c and FAS. Our findings indicate that ACE inhibition with enalapril attenuated several of the deleterious effects of the HF diet. In summary, enalapril appears to be responsible for the normalization of islet morphology and function, a protective role against hepatic insulin resistance and lipid accumulation in the liver. These protective effects of enalapril were attributed, primarily, to the reduction in body mass gain and food intake, increasing EE, the enhancement of the ACE2/Ang (1-7)/Mas receptor axis and adiponectin levels, enhancing hepatic insulin action, leptin and gluconeogenesis, and attenuating NAFLD.